Galenica

Galenica increased sales from January to September by 5.7% to CHF 3.17 billion, driven by the pharmacy business, Home Care and the newly built Diagnostics division. The Products & Care segment grew by 10.9% thanks to strong demand for GLP‑1 preparations and rheumatology drugs, while Logistics & IT rose by only 2.7% and lagged expectations. Analyst expectations were missed overall, but the company confirmed its full-year targets of +5–7% sales growth and +6–8% adjusted operating profit, and a dividend at least at last year’s level. After the IT switchover at Galexis, management expects stronger momentum in the final quarter. » Más en finanzen.net

Galenica increased revenue in the first half by 7.1% to CHF 2.14 billion and adjusted EBIT by 7.1% to just under CHF 118 million; net profit was around CHF 92 million (+1.3%). Drivers were the pharmacy business and wholesale, particularly the Products & Care segment (+11.5%) thanks to strong demand for GLP‑1 preparations, and the Diagnostics business following the acquisition of Labor Team. The Logistics & IT segment grew by 4.2% and Galenica gained market share in the pharmacy channel. For 2026 the company confirms its targets: revenue growth of 5–7%, adjusted operating result +6–8% and at least an unchanged dividend; expected one-off costs for the closure of the Bichsel production unit were estimated at around CHF 30 million. » Más en finanzen.net

Galenica continues its growth trajectory in 2026 and confirms the targets set for the year. The company reports continued growth in the new fiscal year. » Más en finanzen.net

Galenica will lay off fewer employees at its Interlaken subsidiary Bichsel than originally planned. The adjustment reduces the scale of the local workforce reduction; no further details on the number of positions affected were given. » Más en finanzen.net

Galenica reports 2025 net sales of CHF 4.136 billion (+5.5%) and adjusted EBIT of CHF 234.8 million (+11.3%). The board proposes an 8.7% dividend increase to CHF 2.50. The acquisition of Labor Team drove investments and net debt to CHF 675 million (2.3x EBITDA), while operating cash flow and free cash flow before M&A rose significantly. For 2026 Galenica expects revenue growth of 5–7% and adjusted EBIT growth of 6–8% (9–11% excluding special items). » Más en de.investing.com